Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 12, 2011, Pages 1723-1724

  Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; NOTE; OVERALL SURVIVAL; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PROGNOSIS; REDUCED INTENSITY CONDITIONING; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; STANDARD OF CARE; TRANSPLANTATION, HOMOLOGOUS;

EID: 81255211516     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.009     Document Type: Note

References (17)

1. Farag S.S., Archer K.J., Mrozek K., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
2. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
3. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
4. Thomas E.D. Bone marrow transplantation for malignant disease. J Clin Oncol 1983, 1:517.
5. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
6. Gale R.P., Champlin R.E. How does bone marrow transplantation cure leukemia?. Lancet 1984, 2:28-30.
7. Champlin R., Khouri I., Anderlini P., et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 2001, 27:S13-S22.
8. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
9. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010, 28:2859-2867.
10. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005, 23:9387-9393.
11. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
12. Ringden O., Labopin M., Ehninger G., et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:4570-4577.
13. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128-135.
14. Popat U., Heslop H.E., Durett A., et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 2006, 37:547-552.
15. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.
16. Farag S.S., Maharry K., Zhang M.J., et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011.
17. Gyurkocza B., Appelbaum F.R. Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. J Natl Compr Canc Netw 2011, 9:319-329. quiz 330.